new glp 1 receptor agonists GLP-1 Agonist Services for Type 2 Diabetes and Obesity Drug Development Current Insights, Advantages and Challenges

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)

Designed in an easy-to-use tablet format, this product provides a convenient alternative to injectable GLP-1 options

About half support the use of GLP-1 weight loss drugs for adults with obesity or weight-related conditions, and a similar share the belief that these drugs should be covered by Medicare and Medicaid.

Here the authors report that D-allulose triggers GLP-1 release in the gut and GLP-1R signaling on vagal afferents, counteracting arrhythmic overeating, obesity and diabetes.

A new case series presents a unique paradox where GLP-1 RA therapy improved quality of life and resolved diarrhea in two women with